Group News - BYHEALTH

Group News

 Home > About Us > Group News

We always have something new



Leading with strategic initiative——2025 Letter to Shareholders from the Chairman of BYHEALTH

Leading with strategic initiative in 2025 must also focus on eliminating unnecessary work and cutting budgets that do not contribute to product value, user value, or operational value. As a company still in its growth phase, we must avoid turning "operations" into "management," which can lead to premature stagnation and the risks of organizational complacency.

BYHEALTH and Chinese Scientists Collaborate on a Groundbreaking Metabolic Health Evaluation System

BYHEALTH, in collaboration with the Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, and the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences achieved a pioneering breakthrough in their research on a “Homeostasis-Based Health Evaluation System.”

Nature spotlights BYHEALTH R&D innovations on scientific nutrition，including PCC1 and patented probiotics

On June 15, Nature the authoritative scientific journal published a supplement on nutrition researches in China for the first time, and released an interview article EXPLORING NEW FRONTIERS IN HEALTH MANAGEMENT THROUGH NUTRITION RESEARCH, highlighted several cutting-edge research results of BYHEALTH R&D innovations on scientific nutrition, including PCC1 and patented probiotics.

The World’s First Large-scale Study of Association of NAD⁺ Contents with Aging

The research is jointly directed by Shanghai General Hospital Affiliated to School of Medicine, Shanghai Jiao Tong University (SJTU), Jinan University and BYHEALTH Nutrition and Health Research Institute, in collaboration with many other famous national and international institutions of higher education and scientific research institutes.

Two National Invention Patents Conferred on BYHEALTH’s Self-developed Indigenous Strain

China's local probiotics family welcomes another new member. With 7 years of strenuous effort, Lactobacillus Paracasei LPB27, a fine intestinal strain originated from healthy Chinese infants, sees the light of day.



News

2026 Letter to Shareholders from the Chairman of BYHEALTH

2026 Letter to Shareholders from the Chairman of BYHEALTH

October 28 – At the 30th-anniversary celebration of BYHEALTH, Chairman Liang Yunchao delivered a speech titled Thirty Years of Honing, Embarking on Entrepreneurship Once Again. Liang Yunchao stated that BYHEALTH will confront significant challenges head-on. After the sharp decline in 2024 and stabilization in 2025, BYHEALTH will launch a full-scale offensive in 2026 with an entrepreneurial mindset, aiming to achieve new revenue highs between 2026 and 2028 and outperform the growth rates of major industry/category segments across all channels.

Liang Yunchao, Chairman of BYHEALTH: Stand Tall at 30, Re-entrepreneurship in Motion

Liang Yunchao, Chairman of BYHEALTH: Stand Tall at 30, Re-entrepreneurship in Motion

October 28 – At the 30th-anniversary celebration of BYHEALTH, Chairman Liang Yunchao delivered a speech titled Thirty Years of Honing, Embarking on Entrepreneurship Once Again. Liang Yunchao stated that BYHEALTH will confront significant challenges head-on. After the sharp decline in 2024 and stabilization in 2025, BYHEALTH will launch a full-scale offensive in 2026 with an entrepreneurial mindset, aiming to achieve new revenue highs between 2026 and 2028 and outperform the growth rates of major industry/category segments across all channels.

BYHEALTH Vision and Mission (2.0)

BYHEALTH Vision and Mission (2.0)

Nurturing life with science, we create incremental value for consumer health. In a future where human lifespan continues to extend, we strive to enhance life quality, expand life's possibilities, and become a global leader in consumer health.

Leading with strategic initiative——2025 Letter to Shareholders from the Chairman of BYHEALTH

Leading with strategic initiative——2025 Letter to Shareholders from the Chairman of BYHEALTH

Leading with strategic initiative in 2025 must also focus on eliminating unnecessary work and cutting budgets that do not contribute to product value, user value, or operational value. As a company still in its growth phase, we must avoid turning "operations" into "management," which can lead to premature stagnation and the risks of organizational complacency.

BYHEALTH and Chinese Scientists Collaborate on a Groundbreaking Metabolic Health Evaluation System

BYHEALTH and Chinese Scientists Collaborate on a Groundbreaking Metabolic Health Evaluation System

BYHEALTH, in collaboration with the Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, and the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences achieved a pioneering breakthrough in their research on a “Homeostasis-Based Health Evaluation System.”

2024 Letter to the Shareholders from the Chairman of BYHEALTH

2024 Letter to the Shareholders from the Chairman of BYHEALTH

The year 2023 marked the beginning of a new cycle for the dietary supplements (VDS) industry. In the post-pandemic era, public health awareness surged, and in January 2023, there was an explosive demand for categories such as Immune Support, leading to a rapid increase in the VDS industry penetration within a short period of time.

<
1
2
3
4
>